B+
Bull case
20%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-11-06 · RankAlpha Sentiment Codex
XCUR
ExicureDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
$0.89-$0.06 (-6.26%)
At close · 2026-11-09
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-11-06 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.15
Analysis reference price unavailable
Analysis 2026-11-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-11-06
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+36.9
Score
AI commentary
Cautious-to-negative. The November 5 anchor is a 10.34% decline from the prior close, but no verified earnings release links that move to results, guidance, or management commentary; it should not be labeled a post-print reaction. Price record The scheduled earnings trigger remains unconfirmed, and analyst revisions or target changes were not found. Sparse coverage limits confidence despite strong filing evidence for liquidity and listing risks.
RankAlpha Sentiment Codex - 2026-11-06
Open post-earnings memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-30eventUnverified scheduled earnings follow-upHigh impact
The queue identifies November 5 as an earnings date, but no corresponding company earnings release or Q3 filing was verified. The next company report, when available, should clarify cash, R&D spending, funding plans, and listing compliance; no earnings beat or miss can yet be assessed. The last verified quarterly operating baseline is the June 2026 10-Q [#10-Q-2026-08-14]. SEC filing
2026-12-02eventNasdaq equity-compliance deadlineHigh impact
Nasdaq granted Exicure until December 2, 2026 to demonstrate compliance with its stockholders’ equity requirement. The extension is not a finding that compliance has been regained, and failure could lead to a delisting determination [#8-K-2026-09-16] [#SEC-8K-2026-09-16]. SEC filing
2026-12-31catalystFinancing and liquidityHigh impact
Exicure reported $1.7 million of cash at June 30, 2026, no first-half financing cash inflow, and substantial doubt about its ability to continue as a going concern. A funding transaction could preserve operations but may dilute shareholders; failure to obtain funding could threaten them [#10-Q-2026-08-14] [#SEC-10Q-2026-08-14]. SEC filing
Recommendation
N/A
No formal recommendation provided.
As of 2026-11-06 • Updated nightlySource: Internal modelMethodology